AU2019349624B2 - Ketamine composition for use in a method of treatment of depression by pulmonary administration - Google Patents

Ketamine composition for use in a method of treatment of depression by pulmonary administration

Info

Publication number
AU2019349624B2
AU2019349624B2 AU2019349624A AU2019349624A AU2019349624B2 AU 2019349624 B2 AU2019349624 B2 AU 2019349624B2 AU 2019349624 A AU2019349624 A AU 2019349624A AU 2019349624 A AU2019349624 A AU 2019349624A AU 2019349624 B2 AU2019349624 B2 AU 2019349624B2
Authority
AU
Australia
Prior art keywords
ketamine
composition
use according
dry powder
esketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019349624A
Other languages
English (en)
Other versions
AU2019349624A1 (en
Inventor
Sylwia JANOWSKA
Maciej Wieczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novohale Therapeutics LLC
Original Assignee
Novohale Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novohale Therapeutics LLC filed Critical Novohale Therapeutics LLC
Publication of AU2019349624A1 publication Critical patent/AU2019349624A1/en
Assigned to NOVOHALE THERAPEUTICS, LLC reassignment NOVOHALE THERAPEUTICS, LLC Request for Assignment Assignors: CELON PHARMA S.A.
Application granted granted Critical
Publication of AU2019349624B2 publication Critical patent/AU2019349624B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2019349624A 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration Active AU2019349624B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18461615.9 2018-09-28
EP18461615.9A EP3628313B1 (en) 2018-09-28 2018-09-28 Ketamine composition for use in a method of treatment of depression by pulmonary administration
PCT/EP2019/075735 WO2020064748A1 (en) 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration

Publications (2)

Publication Number Publication Date
AU2019349624A1 AU2019349624A1 (en) 2021-04-29
AU2019349624B2 true AU2019349624B2 (en) 2025-08-28

Family

ID=63713806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019349624A Active AU2019349624B2 (en) 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration

Country Status (14)

Country Link
US (1) US11925607B2 (https=)
EP (3) EP3628313B1 (https=)
JP (1) JP7444864B2 (https=)
KR (1) KR102867739B1 (https=)
CN (1) CN113038941A (https=)
AU (1) AU2019349624B2 (https=)
BR (1) BR112021005687A2 (https=)
CA (1) CA3114325A1 (https=)
EA (1) EA202190724A1 (https=)
ES (2) ES3021221T3 (https=)
HU (2) HUE071303T2 (https=)
MX (1) MX2021003668A (https=)
PL (2) PL3628313T3 (https=)
WO (1) WO2020064748A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151191A1 (en) * 2006-03-22 2017-06-01 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
WO2019129397A1 (en) * 2017-12-29 2019-07-04 Celon Pharma S.A. Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
DK2968221T3 (da) 2013-03-15 2019-08-05 Janssen Pharmaceutica Nv Farmaceutisk sammensætning af s-ketaminhydrochlorid
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
KR20170040800A (ko) * 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151191A1 (en) * 2006-03-22 2017-06-01 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
WO2019129397A1 (en) * 2017-12-29 2019-07-04 Celon Pharma S.A. Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers", CLINICALTRIALS.GOV, 12 July 2018. [retrieved from the internet on 2024-08-13] *
CARLA M CANUSO ET AL: "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk ...", AMERICAN JOURNAL OF PSYCHIATRY, 2018, vol. 175, issue 7, pp 620-630. *
K JONKMAN ET AL: "Ketamine inhalation", BRITISH JOURNAL OF ANAESTHESIA. 2017, vol. 118, issue 2, pp 268-269. *
KELLY JONKMAN ET AL: "Pharmacokinetics and Bioavailability of Inhaled Esketamine in Healthy Volunteers :", ANESTHESIOLOGY., vol. 127, no. 4, October 2017 (2017-10-01), PHILADELPHIA, PA, US, pages 675 - 683. *

Also Published As

Publication number Publication date
AU2019349624A1 (en) 2021-04-29
US20210353560A1 (en) 2021-11-18
PL3628313T3 (pl) 2025-06-23
KR20210068465A (ko) 2021-06-09
MX2021003668A (es) 2021-08-19
JP7444864B2 (ja) 2024-03-06
EA202190724A1 (ru) 2021-08-18
BR112021005687A2 (pt) 2021-06-22
EP3856159B1 (en) 2025-03-12
ES3021221T3 (en) 2025-05-26
EP4578505A2 (en) 2025-07-02
WO2020064748A1 (en) 2020-04-02
EP3628313A1 (en) 2020-04-01
HUE071303T2 (hu) 2025-08-28
US11925607B2 (en) 2024-03-12
JP2022502429A (ja) 2022-01-11
EP3856159C0 (en) 2025-03-12
HUE071649T2 (hu) 2025-09-28
CN113038941A (zh) 2021-06-25
CA3114325A1 (en) 2020-04-02
EP3628313C0 (en) 2025-02-12
EP3856159A1 (en) 2021-08-04
ES3028459T3 (en) 2025-06-19
EP3628313B1 (en) 2025-02-12
PL3856159T3 (pl) 2025-06-16
KR102867739B1 (ko) 2025-10-13
EP4578505A3 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
US12440440B2 (en) Dry powder esketamine composition for use in the treatment of bipolar depression by pulmonary administration
US10517828B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
US20220230723A1 (en) Electronically Supervised Administration of a Pharmaceutical Composition
AU2019349624B2 (en) Ketamine composition for use in a method of treatment of depression by pulmonary administration
EA044969B1 (ru) Композиция кетамина для применения в способе лечения депрессии путём ингаляционного введения
EA046690B1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
AU2013100008B4 (en) Inhalable formulations of glycopyrronium bromide
WO2022123607A1 (en) Pharmaceutical formulations of esketamine

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVOHALE THERAPEUTICS, LLC

Free format text: FORMER APPLICANT(S): CELON PHARMA S.A.

FGA Letters patent sealed or granted (standard patent)